Tech Company Financing Transactions
Diakonos Oncology Funding Round
Diakonos Oncology, operating out of Trophy Club, scored $20 million from Baylor Angel Network and private investors.
Transaction Overview
Company Name
Announced On
6/1/2025
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
private investors (Mike Wicks)
Proceeds Purpose
The company intends to use the funds to accelerate its Phase 2 glioblastoma trial for dubodencel, also known as DOC1021, and expand its clinical portfolio to other indications, including refractory melanoma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Shields Court
Trophy Club, TX 76262
USA
Trophy Club, TX 76262
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Diakonos Oncology, a clinical-stage biotechnology entity, was founded to address the critical and unmet medical need of late-stage and aggressive cancers . With a FDA Fast Track designation and unprecedented results in cancers such as Glioblastoma Multiforme (GBM), Diakonos moves closer each day to changing patient outcomes for these difficult indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Dan Faust
Chief Executive Officer
Mike Wicks
Chief Operating Officer
Jay Hartenbach
Chief Scientific Officer
Will Decker
Chief Technical Officer
Matt Halpert
VP - Finance
Marcus Gohlke
VP - R & D
Vanaja Konduri
VP - Regulatory Affairs
Ian Bellayr
VP - Regulatory Affairs
Moya Daniels
Browse more venture capital transactions:
Prev: 5/31/2025: Portless venture capital transaction
Next: 6/2/2025: Rally UXR venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs